Dec. 16, 2024 — A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. Researchers have discovered that an ...

Federal agencies have funded more than a billion dollars in biomedical research in Maine over the past 10 years.

Muscular dystrophy, loss of mobility ... be taken to support better nutrition with this disease. People with DMD face a number of challenges to their nutritional health, including both over ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing severe muscle degeneration, also profoundly affects the brain ...

Colton Belluzzo was diagnosed with a form of muscular dystrophy when he was a baby. The disease has weakened his muscles over time. But he and his family now have good reason to be optimistic.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

The 11-year-old's strength and bravery in living with the impact of the serious muscle-wasting condition was hailed by her ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a ...

FSHD is the second most common form of muscular dystrophy after the Duchenne type ... It tends to cause muscle wasting in the face, shoulder blades, and upper arms. The deal – which includes ...

Born with Duchenne muscular dystrophy and diagnosed at 4 months old in 1996, he is currently based in the Eastern part of Singapore. His hope for his column is to advocate for the health and ...

The collaboration between Muscular Dystrophy UK, the leading charity for over 110,000 people in the UK living with one of ...

The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period ...